01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

More documents

Recommendations

Info

158. Naked Plasmid DNA Gene Therapy /Phase I /Colon /Immunotherapy 159. Gene Therapy /Phase I /Other /Peripheral Artery Disease 160. Gene Therapy /Phase I /Other /Restenosis 161. Gene Therapy /Phase I /II /Cancer /Non- Hodgkin’s B-Cell Lymphoma /Mantle Cell Lymphoma /Immumotherapy 162. Gene Therapy /Phase I /Cancer /Malignant Glioma /Antisense 163. Gene Therapy /Phase I- IB /Cancer /Melanoma or Sarcoma /Immunotherapy 164. Gene Therapy /Phase I /Other /Cubital Tunnel Syndrome 165. Adeno-Associated Virus Gene Therapy /Phase I /Monogenic Disease /Cystic Fibrosis 166. Gene Therapy /Phase II /Monogenic Inherited Disorder /Cystic Fibrosis /Sinusitis /Correction 167. IMMUNOTHERAPY or OTHER Gene Therapy /Phase I /Monogenic Disease /Familial Hypercholesterolemia 168. Gene Therapy /Phase I /Infectious Disease /Human Immunodeficiency Virus /Replication Inhibition /Antisense 169. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 170. Gene Therapy /Phase I /Cancer /CEA- Expressing Malignancies (type of Sponsor: GenVec, Inc. Boulikas: An overview on gene therapy Phase I Trial of a Polynucleotide Augmented Anti- Tumor Immunization to Human Carcinoembryonic Antigen in Patients with Metastatic Colorectal Cancer. Arterial Gene Transfer for Therapeutic Angiogenesis in Patients with Peripheral Artery Disease. Accelerated Re-endothelialization and Reduced Neointimal Thickening Following Catheter Transfer of phVEGF165. A Phase I /II Study of Vaccine Therapy for B-Cell Lymphoma Utilizing Plasmid DNA Coding for Tumor Idiotype. Sponsor: Vical, Inc. A Phase I Study of the Safety of Injecting Malignant Glioma Patients with Irradiated TGF-ß2 Antisense Gene Modified Autologous Tumor Cells. Phase I /IB Study of Immunization with Autologous Tumor Cells Transfected with the GM-CSF Gene by Particle-Mediated Transfer in Patients with Melanoma or Sarcoma. Phase I Single Dose-Ranging Study Of Formulated hIGF-I Plasmid In Subjects With Cubital Tunnel Syndrome. Sponsor: Gene Medicine, Inc. A Phase I Study of an Adeno-associated Virus- CFTR Gene Vector in Adult CF Patients with Mild Lung Disease. Sponsor: Targeted Genetics Corporation A Phase I /II Study of tgAAVCF for the Treatment of Chronic Sinusitis With Cystic Fibrosis. Sponsor: Targeted Genetics Corporation Ex Vivo Gene Therapy of Familial Hypercholesterolemia. Gene Therapy for AIDS using Retroviral Mediated Gene Transfer to deliver HIV-1 Antisense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV Infected Identical Twins. Phase I Study of Tumor-Infiltrating Lymphocytes Derived from In Vivo HLA-B7 Gene Modified Tumors in the Adoptive Immunotherapy of Melanoma. A Study of Recombinant ALVAC Virus that Expresses Carcinoembryonic Antigen in Patients with Advanced Cancers. 178 In Vivo /Autologous Tumor Cells /Plasmid DNA /Carcinoembryonic Antigen Plasmid Expression Vector /Kanamycin Resistance cDNA /Intratumoral /Direct Injection In Vivo /Vascular Endothelial Cells /Plasmid DNA /Vascular Endothelial Growth Factor cDNA /Intraarterial /Angioplasty Catheter /Hydrogel Coated Balloon In Vivo /Vascular Endothelial Cells /Plasmid DNA /Vascular Endothelial Growth Factor cDNA /Intraarterial /Angioplasty Catheter /Hydrogel Coated Balloon In Vivo /Naked Plasmid DNA /Tumor Idiotype /Intramuscular Injection In Vitro /Autologous Tumor Cells /Lethally Irradiated /Plasmid DNA--Electroporation /TGFß2 /Subcutaneous Injection In Vitro /Autologous Tumor Cells /Lethally Irradiated /Plasmid DNA /Particle Mediated Gene Transfer (Accell®) /Cytokine /GM-CSF cDNA /Subcutaneous Injection In Vivo /Autologous Muscle Cells /Plasmid DNA /Polyvinylpyrrolidone (PVP) /Human Insulin-Like Growth Factor-1(hIGF-1) /Intramuscular Injection In Vivo /Nasal Epithelial Cells /Respiratory Epithelial Cells /Adeno-Associated Virus /Cystic Fibrosis Transmembrane Conductance Regulator cDNA /Intranasal /Respiratory Tract Administration (Bronchoscope) In Vivo /Maxillary Sinus Epithelial Cells / Adeno-Associated Virus /Cystic Fibrosis Transmembrane Conductance Regulator cDNA /Maxillary Sinus Administration In Vitro /Low Density Lipoprotein Receptor cDNA /Intrahepatic /Portal Vein Catheter In Vitro /Antisense TAR /Transdominant Rev /Intravenous In Vivo /Autologous Tumor Cells /Used to Derive Tumor Infiltrating Lymphocytes /HLA- B7 cDNA /Intravenous In Vivo /Autologous Muscle Cells /Canarypox Virus /Carcinoembryonic Antigen cDNA /Intramuscular Injection Curiel, David Isner, Jeffrey M. and Walsh, Kenneth Isner, Jeffrey, M Levy, Ronald Black, Keith L. and Fakhrai, Habib Mahvi, David M Netscher, David Flotte, Terence R and Zeitlin, Pamela L Gardner, Phyllis Wilson, James M Morgan, Richard and Walker, Robert Chang, Alfred E. and Nabel, Gary J Hawkins, Michael J. and Marshall, John L
cancer not specified) /Immunotherapy 171. Gene Therapy /Phase I /Cancer /Prostate Adenocarcinoma /Immunotherapy 172. Gene Therapy /Phase I /Cancer /Gastrointestinal Tract, Breast, or Lung Adenocarcinoma (CEA- Expressing Malignancies) /Immunotherapy 173. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 174. Gene Therapy /Phase I /Cancer /Prostate Adenocarcinoma /Immunotherapy 175. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 176. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 177. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 178. Gene Therapy /Phase I /II /Cancer /Prostate Adenocarcinoma /Immunotherapy 179. Gene Therapy /Phase I /Cancer /CEA- Expressing Malignancies /Immunotherapy 180. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy 181. Gene Therapy /Phase I /Cancer /Immunotherapy /CEA-Expressing Malignancies 182. Gene Therapy /Phase I /Cancer /Immunotherapy /CEA-Expressing Malignancies 183. Gene Therapy /Phase I /Cancer /Melanoma /Immunotherapy Gene Therapy and Molecular Biology Vol 1, page 179 A Phase I Study of Recombinant Vaccinia that Expresses Prostate Specific Antigen in Adult Patients with Adenocarcinoma of the Prostate. Phase I Study of Recombinant CEA Vaccinia Virus Vaccine with Post Vaccination CEA Peptide Challenge. Evaluation of Intratumoral Gene Therapy with HLA-B7 /DMRIE /DOPE plus Subcutaneous Low Dose Il-2. A Phase I Trial Of Recombinant Vaccina Virus That Expresses PSA In Patients With Adenocarcinoma Of The Prostate. Phase I Trial In Patients With Metastatic Melanoma Of Immunization With A Recombinant Fowlpox Virus Encoding The MART-1 Melanoma Antigen. Phase I Trial In Patients With Metastatic Melanoma Of Immunization With A Recombinant Fowlpox Virus Encoding the GP100 Melanoma Antigen. Phase I Trial In Patients With Metastatic Melanoma Of Immunization With A Recombinant Vaccinia Virus Encoding the MART-1 Melanoma Antigen. A Phase I /II Clinical Trial Evaluating the Safety and Biological Acivity of Recombinant Vaccinia-PSA Vaccine in Patients with Serological Recurrence of Prostate Cancer Following Radical Prostatectomy. A Phase I Study of Active Immunotherapy With Carcinoembronic Antigen RNA-Pulsed Autologous Human Cultured Dendritic Cells In Patients Wlth Metastatic Malignancies Expressing Carcinoembryonic Antigen. Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding the Human Interleukin-12 Gene (ALVAC-hIL-12) in Patients with Surgically Incurable Melanoma Sponsor: NCI- Cancer Therapy Evaluation Program A Pilot Study of Sequential Vaccinations with ALVAC-CEA and Vaccina-CEA with the addition of IL-2 and GM-CSF in Patients with CEA Expressing Tumors Sponsor: National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) A Phase I Trial of a Recombinant Vaccinia-CEA (180 Kd) Vaccine Delivered by Intradermal Needle Injection Versus Subcutaneous Jet Injection in Patients with Metastatic CEA-Expressing Adenocarcinoma Sponsor: NCI, NIH Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding 179 In Vivo /Vaccination /Vaccinia Virus /Prostate Specific Antigen /Intradermal Injection In Vivo /Vaccination /Vaccinia Virus /Carcinoembryonic Antigen /Intradermal Injection in Combination with Subcutaneous Peptide Challenge In Vivo /Autologous Tumor Cells /HLA B7 cDNA /Intratumoral /Concurrent Interleukin-2 Therapy In Vivo /Vaccination /Vaccinia Virus /Prostate Specific Antigen /Intradermal Injection In Vivo /Fowlpox Virus /MART-1 Melanoma Antigen /Intramuscular Injection In Vivo /Fowlpox Virus /gp100 Melanoma Antigen /Intramuscular Injection In Vivo /Vaccinia Virus /MART-1 Melanoma Antigen /Intramuscular Injection In Vivo /Vaccination /Vaccinia Virus /Prostate Specific Antigen /Intradermal Injection In Vitro /Autologous Dendritic Cells /RNA Transfer /Carcinoembryonic Antigen /Intravenous In Vivo /Autologous Melanoma Cell /Canarypox Virus /Cytokine /Interleukin-12 cDNA /Intratumoral Injection In Vivo /Autologous Muscle Cells /Canarypox Virus /Vaccinia Virus /Carcinoembryonic Antigen cDNA /Intramuscular and Percutaneous Injection In Vivo /Vaccinia Virus /Carcinoembryonic Antigen cDNA /Intradermal and Subcutaneous Injections InVivo /Autologous Melanoma Cell /Canarypox Virus /B7(CD80) /Interleukin-12 /Cytokine /Intratumoral Injection Chen, A.P Cole, David J Hersh, Evan M and Sondak, Vernon K. Kufe, Donald W., and Eder, Joseph Paul Rosenberg, Steven A Rosenberg, Steven A Rosenberg, Steven A Sanda, Martin G Lyerly, Kim H Conry, Robert M Marshall, John L Conry, Robert M Conry, Robert M
Page 1 and 2:
Gene Ther Mol Biol Vol 1, 1-172. Ma
Page 3 and 4:
I. Introduction Monumental progress
Page 5 and 6:
The use of retroviral vectors in hu
Page 7 and 8:
displaying the cleavable EGF domain
Page 9 and 10:
molecules in the nucleus (Lowe and
Page 11 and 12:
sensitive mutations which allow pro
Page 13 and 14:
processed as described in panel A s
Page 15 and 16:
On the contrary, the payload capaci
Page 17 and 18:
in K562 human erythroleukemia cells
Page 19 and 20:
defective HSV virus (DeLuca and Sch
Page 21 and 22:
complex into the cytosol from the e
Page 23 and 24:
Gene Therapy and Molecular Biology
Page 25 and 26:
delivered by Sendai virus-liposome
Page 27 and 28:
plasmids with the cell surface, tra
Page 29 and 30:
infected by adenovirus alone; infec
Page 31 and 32:
Page 33 and 34:
B. Transcription factor binding sit
Page 35 and 36:
A closely related family of ubiquit
Page 37 and 38:
cells. I-CreI is a member of this c
Page 39 and 40:
Page 41 and 42:
C. Considerations of chromatin stru
Page 43 and 44:
Page 45 and 46:
A. The molecular basis of cancer im
Page 47 and 48:
fragments, or heat shock proteins c
Page 49 and 50:
ecombinant vaccinia virus expressin
Page 51 and 52:
HIV-1 envelope DNA construct develo
Page 53 and 54:
inding sites A GYYY oriented in opp
Page 55 and 56:
Page 57 and 58:
Prives, 1994). Whereas the wild-typ
Page 59 and 60:
mutant p53 (mutations on p53 are wi
Page 61 and 62:
master regulator of the cell cycle
Page 63 and 64:
Work from several groups has shown
Page 65 and 66:
chromatin condensation, drop in pH,
Page 67 and 68:
Figure 23. A pathway leading to the
Page 69 and 70:
Excessive necrotic death in cells o
Page 71 and 72:
implantation, and similar processes
Page 73 and 74:
normal cells in the surroundings. T
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
A bicistronic retroviral vector (Ha
Page 81 and 82:
C. Antisense ras gene transfer for
Page 83 and 84:
equal to 6.0 showed S1 hyperreactiv
Page 85 and 86:
protein (e.g. Smith et al, 1995; Fo
Page 87 and 88:
transduced primary mouse fibroblast
Page 89 and 90:
IL-1 - receptor antagonist protein
Page 91 and 92:
p53 lung cancer retroviru s MHC cla
Page 93 and 94:
Page 95 and 96:
designed by immunization with porti
Page 97 and 98:
Isolation of an RNA aptamer that ca
Page 99 and 100:
induction of human apoE in neonate
Page 101 and 102:
atrium in heart, endothelial cells
Page 103 and 104:
which eliminated tumors in small an
Page 105 and 106:
C. Transfer of other genes against
Page 107 and 108:
Page 109 and 110:
significant reduction in neointima
Page 111 and 112:
(Prehn et al, 1996); this implies a
Page 113 and 114:
B. Approaches to gene therapy of RA
Page 115 and 116:
of human immunoglobulin and antigen
Page 117 and 118:
A. Etiology and mechanisms of destr
Page 119 and 120:
Page 121 and 122:
However, CsA also inhibits the acti
Page 123 and 124:
The peptide kinin, after binding to
Page 125 and 126:
intake when administered to adrenal
Page 127 and 128: Introgen Therapeutics (Austin and H
Page 129 and 130: When a subfragment of only 513 bp o
Page 131 and 132: Armentano D, Zabner J, Sacks C, Soo
Page 133 and 134: Brady HJM, Miles CG, Pennington DJ,
Page 135 and 136: Chen J, Stickles RJ, Daichendt KA (
Page 137 and 138: Day ML, Wu S, Basler JW (1993) Pros
Page 139 and 140: Farmer G, Bargonetti J, Zhu H, Frie
Page 141 and 142: Giovannangeli C, Perrouault L, Escu
Page 143 and 144: the neoplastic phenotype by replace
Page 145 and 146: integrate in a site-specific fashio
Page 147 and 148: Li R, Waga S, Hannon GJ, Beach D, S
Page 149 and 150: adiation-induced apoptosis in the g
Page 151 and 152: Nakaya T, Iwai S, Fujinaga K, Sato
Page 153 and 154: Polyak K, Xia Y, Zweier JL, Kinzler
Page 155 and 156: macrophages from simian immunodefic
Page 157 and 158: intimal hyperplasia in a rat caroti
Page 159 and 160: Trono D, Feinberg MB, Baltimore D (
Page 161 and 162: Wattiaux R, Jadot M, Warnier-Pirott
Page 163 and 164: similar to mammalian interleukin-1
Page 165 and 166: Gene Therapy and Molecular Biology
Page 167 and 168: 24. Gene Marking /Infectious Diseas
Page 169 and 170: Drug 50. Gene Therapy /Phase I /Can
Page 171 and 172: 76. Gene Therapy /Phase I /Cancer /
Page 173 and 174: 99. Gene Therapy /Phase II /Cancer
Page 175 and 176: 120. Gene Therapy /Phase I /Monogen
Page 177: Gene Therapy and Molecular Biology
show all

01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?